BIOCYTOGEN
21.6.2024 12:51:24 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Launches AgenticIQ™, an End-to-End Agentic AI Platform for Engineering, Manufacturing and Customer Experience11.8.2026 11:30:00 CEST | Press release
Highlights:Purpose-built to help organizations scale autonomous, domain-aware AI agents from pilots to productionLays the foundation for LTTS’ next-generation Engineering Intelligence solutions and Agentic-led engineering delivery L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of AgenticIQ™, an end-to-end Agentic AI platform purpose-built for engineering and manufacturing organizations. Designed to help enterprises move beyond isolated AI pilots, AgenticIQ™ enables autonomous, multi-agent workflows across engineering, product development, manufacturing, industrial operations and customer experience, accelerating the adoption of Engineering Intelligence at scale. As enterprises increase investments in AI, many initiatives continue to struggle to move beyond proof-of-concepts into production. Disconnected engineering systems, manual processes and highly regulated environments o
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 202611.8.2026 11:00:00 CEST | Press release
Recognition highlights the MultiBank Group Founder and Chairman’s leadership, global experience and contribution to the financial services industry MultiBank Group, one of the world’s largest and most regulated financial derivatives institutions, has announced that its Founder and Chairman, Naser Taher, has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811229836/en/ Naser Taher has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. The annual Forbes Middle East Top 100 CEOs list celebrates prominent business leaders who are shaping the region’s corporate landscape and leading organisations with significant scale, influence and impact. The ranking brings together
teamLab Unveils New Series from Light Sculpture - Flow at teamLab Borderless. Special Exhibit, "On the Asymmetry of the Universe," on View Through October 811.8.2026 11:00:00 CEST | Press release
teamLab reopens the Light Sculpture - Flow series artwork space at teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Azabudai Hills, Tokyo from July 8, 2026. To commemorate the reopening, teamLab unveils two new series, Asymmetric Existence and Chromatic Existence, featured in the special exhibit "On the Asymmetry of the Universe." The special exhibit, “On the Asymmetry of the Universe,” runs from Wednesday, July 8, 2026 through Thursday, October 8, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807256066/en/ Light Sculpture - Flow The inside and outside of an ocean vortex are composed of the same water; there is no material difference between them. Yet, despite this, why do we perceive a vortex as a singular entity, or even sense a form of life within it? The difference between the inside and outside of a vortex lies in the order, not the material. When order is born within a flow, existence emerges even with
KIOGE 2026 Marks 30 Years of Connecting the Global Energy Industry with Central Asia11.8.2026 10:21:00 CEST | Press release
30 September – 2 October 2026 As Kazakhstan strengthens its position as one of Eurasia's leading energy markets, KIOGE 2026 – the 30th Kazakhstan International Oil & Gas Exhibition and Conference – invites international companies to explore business opportunities and establish partnerships across Central Asia's evolving oil and gas sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811699632/en/ Almassadam Satkaliyev, Minister of Energy of the Republic of Kazakhstan in 2024, speaking at KIOGE (Photo: AETOSWire) For three decades, KIOGE has connected global manufacturers, technology providers, EPC contractors, service companies and investors with key decision-makers shaping Kazakhstan's energy industry. For companies entering the market or expanding their regional presence, the event provides direct access to one of Central Asia's most significant energy economies. KIOGE 2026 has already attracted more than 235 compani
Cambridge International AS & A Level Entries Grow 5% Amid Rising Higher Education Demand for Flexible, Skills-Based Qualifications11.8.2026 08:03:00 CEST | Press release
Around 368,000 Cambridge International AS & A Level students receive results todayNearly 705,000 students in 148 countries sat Cambridge exams in the June series, with total entries up to 1.7 million Cambridge International Education (Cambridge) has begun releasing the results of its June 2026 exam series to students worldwide. Entries for Cambridge International AS & A Levels rose 5% on last year, with almost 368,000 students in 3492 schools worldwide receiving Cambridge International AS & A Level results today. This continued growth reflects the increasing global demand for qualifications that provide a trusted route to higher education. Recognised by more than 2500 universities worldwide, Cambridge International AS & A Levels equip learners with the academic knowledge, independent thinking and problem-solving skills needed to succeed at university and beyond. Their acceptance now extends well beyond traditional destinations such as the UK, the US, Canada and Australia, with leading
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom